Skip Navigation

Annals of Oncology 2008 19(6):1036-1037; doi:10.1093/annonc/mdn357
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hayes, D. N.
Right arrow Articles by McLeod, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, D. N.
Right arrow Articles by McLeod, H. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorials

EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose

D. N. Hayes* and H. L. McLeod

The Lineberger Comprehensive Cancer Center, UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Hematology and Oncology and Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC, USA

* (E-mail: hayes@med.unc.edu)

The first 10% of the full text of this article appears below.

Since it was first described 40 years ago, the epidermal growth factor (EGF) and its receptor (EGFR) has become one of the most studied entities in all human biology [1, 2]. The potent role of EGF in transforming normal cells into tumors was an early observation with specific implications for lung cancer clear by the early 1980s [3, 4]. In 1980, the gene was localized to chromosome 7, opening the door for consideration of the complex set of genetic aberrations now described for the EGFR locus [5]. In the intervening quarter century, many downstream regulatory and signaling events have been reported, most . . . [Full Text of this Article]

funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?